Eagle.i
Our breakthrough non-invasive Anti-VEGF topical formulation is a patient-preferred alternative to injections for AMD, Diabetic Retinopathy and more.
Imagine if we can give the gift of sight extending quality of life for 300+ million patients diagnosed with AMD, Diabetic Retinopathy or Central Retinal Vein Occlusion.
The current treatment is expensive Anti-VEGF injections into the eye given on a 4 to 6 weekly basis. The treatment is so expensive, risky and burdensome that many do not access treatment and over 70% fail to continue once they start.
Governments around the world face a HUGE public health problem with an ageing population, direct and non-direct expenses costing taxpayers and patients hundreds of millions to billions of dollars around the world.
VEGF injections
Galeri Lens Solution
Non-invasive Anti-VEGF
formulation with retinal
permeation
Significant animal trial results,
with improved retinal drug
delivery and minimal serum
concentration
Reduced need for physician
visits, increase patient access to
physicians including remote
care and lower overall costs.
We are seeking seed stage investment to commence our Human Phase 0 trials. Once funding is secured this first trial will be completed in 12 to 18 months. We will then raise our Series A funding to commence Clinical Trials – Phase 1 to 3 and Regulatory Approval.
All Rights Reserved. GALERI © 2025